“Long-Term Safety and Disease Control of Ruxolitinib Cream Among Adolescents With Atopic Dermatitis: Results From Two Phase 3 Studies” (2022) SKIN The Journal of Cutaneous Medicine, 6(2), p. s28. doi:10.25251/skin.6.supp.28.